The effect Pistacia Atlantica seed oil on serum antioxidant status in patients with metabolic syndrome

Not Applicable

• Conditions: Metabolic Syndrome.; Metabolic Syndrome; E88.81

• Registration Number: IRCT20130223012571N8
• Lead Sponsor: Yazd University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 8 March 2022

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

Adults aged 20-50 years
Diagnosed with metabolic syndrome (having at least three of these conditions): abdominal obesity (waist circumference >102 cm in men and >88 cm in women), high blood pressure (systolic blood pressure >130 mmHg or diastolic blood pressure >85 mmHg), low serum high-density lipoprotein cholesterol (serum HDL cholesterol <40 mg/dl in men and <50 mg/dl in women), high serum triglycerides ( serum triglyceride > 150 mg/dl), high blood glucose (fasting blood glucose = 100 mg/dl)

Exclusion Criteria

Diagnosis or reporting a history of cardiovascular disease
Diagnosis or reporting a history of diabetes mellitus
Diagnosis or reporting a history of cancer
Diagnosis or reporting a history of pancreatitis
Diagnosis or reporting a history of liver disease
Diagnosis or reporting a history of kidney disease
Changing the blood sugar and lipid-lowering medications over the past three months
Taking systemic corticosteroids, androgen, phenytoin, erythromycin, Hemostatic regulators (other than aspirin), gastrointestinal medicine less than 30 days before enrollment
History of gastrointestinal disorders
Alcohol use
Being pregnant
Intention to become pregnant
Giving birth in the last 12 months
Having allergy or intolerance to the intervention oils
Reluctance to follow the study protocol
Having weight change over 3 kg two months prior to the study
Taking Omega-3 supplements more than 1 g/day
Smoking more than 20 cigarettes a day
Taking drugs for COVID-19 including remdesivir, Interferon, actemra, favipiravir in the last 3 months

Study & Design

• Study Type: interventional
• Study Design: Not specified